Cilastatin
Primaxin, Recarbrio (cilastatin) is a small molecule pharmaceutical. Cilastatin was first approved as Primaxin on 1985-11-26. It is used to treat bacterial endocarditis, infectious arthritis, infectious bone diseases, infectious skin diseases, and intraabdominal infections amongst others in the USA. It has been approved in Europe to treat gram-negative bacterial infections. The pharmaceutical is active against dipeptidase 1.
| Trade Name | Recarbrio |
|---|---|
| Common Name | Cilastatin |
| Indication | bacterial endocarditis, gram-negative bacterial infections, infectious arthritis, infectious bone diseases, infectious skin diseases, intraabdominal infections, respiratory tract infections, urinary tract infections |
| Drug Class | Enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
